Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2017 December;42(4) > Minerva Endocrinologica 2017 December;42(4):331-9

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Endocrinologica 2017 December;42(4):331-9

DOI: 10.23736/S0391-1977.17.02633-5

Copyright © 2017 EDIZIONI MINERVA MEDICA

language: English

What is new in 2017? Update on fertility preservation in cancer patients

Katharina WINKLER-CREPAZ , Bettina BÖTTCHER, Bettina TOTH, Ludwig WILDT, Susanne HOFER‑TOLLINGER

Department of Gynecological Endocrinology and Reproductive Medicine, Innsbruck Medical University, Innsbruck, Austria


PDF


The prevention of fertility loss due to cancer treatment as well as non-malignant causes has been gaining importance over the last few decades. Clinically applied modalities for fertility preservation in cancer patients include cryopreservation of oocytes and embryos, the application of GnRH agonists, ovarian tissue banking, and cryopreservation of ejaculated or surgically extracted sperm. In addition, several new possibilities to restore fertility are currently being investigated, such as the establishment of in-vitro culture systems for gonadal tissue, the development of artificial gonads, and the application of germline stem cells. This review aims to provide an update on the methods currently applied in clinical practice for fertility preservation, as well as to summarize the progress made in the development of novel strategies for fertility preservation.


KEY WORDS: Fertility preservation - Female fertility agents - Male fertility agents - Neoplasms

top of page